Group 1 - The core point of the article is that Opcon Vision has received a Class III medical device registration certificate for its new product, "soft hydrophilic contact lens," from the National Medical Products Administration of China [1] - Opcon Vision's revenue composition for the year 2024 is as follows: 56.18% from rigid corneal contact lenses, 20.04% from the medical sector, 19.47% from other optometry and professional services, and 4.31% from non-optometry and others [1] - As of the report, Opcon Vision has a market capitalization of 14.4 billion yuan [1]

Core Viewpoint - The company has received regulatory approval for its new medical device product, indicating a significant advancement in its product offerings and potential market opportunities [2]. Company Summary - The company's wholly-owned subsidiary, Opcon Vision Investment Co., Ltd., has a controlling stake in Jiangsu Duozhi Medical Technology Co., Ltd. [2]. - Jiangsu Duozhi Medical has recently obtained the Medical Device Registration Certificate from the National Medical Products Administration of China for its "soft hydrophilic contact lens" product, which is classified as a Class III medical device [2].

Core Insights - The company reported a revenue of 562 million yuan for Q3 2025, representing a year-on-year growth of 2.62% [2] - The net profit attributable to shareholders decreased by 3.10% year-on-year, amounting to 192 million yuan [2] - The basic earnings per share (EPS) stood at 0.216 yuan [2] Financial Performance - Revenue for Q3 2025: 562 million yuan, up 2.62% year-on-year [2] - Net profit for Q3 2025: 192 million yuan, down 3.10% year-on-year [2] - Basic EPS for Q3 2025: 0.216 yuan [2]

Core Viewpoint - The company reported a slight increase in revenue for the first three quarters of 2025, but experienced a significant decline in net profit compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters reached 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, showing a year-on-year decrease of 15.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 392 million yuan, down 17.21% year-on-year [1] - Basic earnings per share were reported at 0.495 yuan [1]

Core Viewpoint - Oupeng Vision (300595.SZ) reported its Q3 results, showing a slight increase in revenue but a significant decline in net profit compared to the previous year [1] Financial Performance - The company's revenue for the first three quarters reached 1.43 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, reflecting a year-on-year decrease of 15.41% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 390 million yuan, down 17.21% year-on-year [1]

Core Insights - The company, Opple Vision (300595), reported a slight increase in revenue for the first three quarters of 2025, with total revenue reaching 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - However, the net profit attributable to the company decreased by 15.41% year-on-year, amounting to 442 million yuan [1] - The decline in net profit was attributed to a decrease in revenue from high-margin hard lenses, while revenue from lower-margin optical products and technical services increased, leading to a lower profit growth rate compared to revenue growth [1] Revenue and Profit Analysis - Revenue for the first three quarters was 1.433 billion yuan, with a year-on-year increase of 0.13% [1] - Net profit attributable to the company was 442 million yuan, showing a year-on-year decline of 15.41% [1] - In the third quarter alone, net profit decreased by 3.1%, which was lower than the revenue growth [1] Cost and Expense Factors - The increase in sales expenses was noted, with a year-on-year rise of 9.75%, and an 8.53% increase in the third quarter [1] - The rise in sales expenses was primarily due to the hiring of additional sales and technical support personnel, as well as promotional activities [1] - Newly established optical terminals generated low initial revenue but incurred high fixed costs, contributing to the increase in revenue without a corresponding increase in profit [1]

Core Viewpoint - The company reported a slight increase in revenue but a significant decline in net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved operating revenue of 1.433 billion yuan, representing a year-on-year growth of 0.13% [1] - The net profit attributable to shareholders was 442 million yuan, showing a year-on-year decrease of 15.41% [1] - Basic earnings per share were 0.4950 yuan, also down by 15.41% year-on-year [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-085 欧普康视科技股份有限公司 欧普康视科技股份有限公司 董事会 二○二五年十月二十五日 1 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司 2025 年第三季度报告于 2025 年 10 月 25 日在中 国证监会指定的创业板信息披露媒体巨潮资讯网（http://www.cninfo.com.cn） 上披露，敬请投资者注意查阅。 特此公告。 ...

欧普康视科技股份有限公司 关于软性亲水接触镜获得医疗器械注册证的公告 证券代码：300595 证券简称：欧普康视 公告编号：2025-087 欧普康视科技股份有限公司（以下简称"公司"）的全资子公司欧普康视投 资有限公司的控股子公司江苏多姿医疗科技有限公司（以下简称"多姿医疗"） 于近日收到国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》（注 册证编号：国械注准 20253162076），多姿医疗的"软性亲水接触镜"新产品已 完成注册并获得第三类医疗器械注册证。现将具体信息公告如下： 一、注册产品基本情况 1、注册人名称：江苏多姿医疗科技有限公司 2、注册人住所：江苏省丹阳市开发区九纬路 1 号 3、生产地址：江苏省丹阳市开发区九纬路 1 号二号楼一层二层、三号楼一 层二层 4、产品名称：软性亲水接触镜 5、注册分类：第三类 6、型号、规格：型号：Rhodos 规格：无 7、结构及组成：该产品为日戴软性亲水接触镜，由 HEMA、NVP、GMMA、EGDMA 及着色剂等聚合而成，着浅蓝色，采用 PP 杯包装。含水量标称值：43%。推荐更 换周期一天。产品经湿热灭菌。货架有效期 5 年。 8、适用范围：日 ...

证券代码：300595 证券简称：欧普康视 公告编号：2025-084 欧普康视科技股份有限公司 第四届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）欧普康视科技股份有限公司（以下简称"公司"）第四届董事会第十 九次会议，于 2025 年 10 月 19 日以专人送达、即时通讯等方式发出会议通知。 （四）本次会议由董事长陶悦群先生主持，公司全体高级管理人员列席会议。 （五）本次会议召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经投票表决，会议审议通过如下决议： 以 9 票赞成，0 票反对，0 票弃权审议通过《欧普康视科技股份有限公司 2025 年第三季度报告》 《欧普康视科技股份有限公司 2025 年第三季度报告》编制和审核程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 2025 年第三季度经营的实际情况，不存在虚假记载、误导性陈述或者重大遗漏。 公司董事会审计委员会已审议通过本议案并同意提交董事会审议。具体内容 详见公司同日在巨潮资讯网（ht ...